New CAR-T cell therapy shows promise for hard-to-treat cancers Date: March 10, 2025 Source: University of Colorado Anschutz Medical Campus Summary: Researchers have successfully developed a ...

CAR-T cell therapy faces accessibility challenges, primarily available at large urban centers, leading to geographic and socioeconomic disparities. The KarMMa-3 study showed Abecma CAR-T therapy ...

CAR-T cell therapy involves extracting a patient’s T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body.

Get Instant Summarized Text (Gist) A new CAR-T cell therapy, ALA-CART, has been developed to enhance the effectiveness and longevity of CAR-T cells against hard-to-treat cancers. This approach ...

CAR-T cell therapy involves extracting a patient's T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body.

While chimeric antigen receptor (CAR) T cell therapy is an essential therapeutic option for prolonging survival in patients with relapsed or refractory non-Hodgkin lymphomas (NHL), profound immune ...

CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...

Despite its promise, autologous chimeric antigen receptor T-cell (CAR T-cell) therapy faces several challenges, including limited accessibility, high costs and manufacturing bottlenecks. Allogeneic ...

Radiation bridging therapy during CAR T-cell manufacturing improves outcomes in R/R LBCL compared to systemic bridging therapy. Axi-cel shows superior overall and complete response rates compared ...

BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to co-develop the prospect, BioNTech let the option expire as part of its ...